![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 35, 24901-24905, August 27, 1999
-Lactams Is
Defined by Two Inhibitor Crystal Complexes*
,
,
,
From the Structural Biochemistry Group and The Edinburgh Centre for
Protein Technology, Institute of Cell and Molecular Biology, The
University of Edinburgh, Michael Swann Building, King's Buildings,
Mayfield Road, Edinburgh EH9 3JR, United Kingdom,
Department of Chemistry and The Edinburgh Centre for
Protein Technology, The University of Edinburgh, King's Buildings,
West Mains Road, Edinburgh EH9 3JJ, United Kingdom, and
§ Nycomed Amersham plc, White Lion Road, Amersham HP7 9LL,
Great Britain
| |
ABSTRACT |
|---|
|
|
|---|
Two structurally related Human leukocyte elastase is an important therapeutic target in view of
its implied role in diseases such as emphysema (5), cystic fibrosis
(6), and rheumatoid arthritis (7). Two x-ray structures of The crystals were grown by the hanging drop method at room
temperature. Porcine pancreatic elastase at 10 mg/ml was incubated with
a 3-fold molar excess of inhibitor for 1.5 h at room temperature before drops were laid. The well solution contained 0.1 M
sodium acetate buffer at pH 5.1 and 55 mM sodium sulfate.
The drops consisted of 2 µl of protein and 2 µl of well solution.
Crystals of approximate dimensions 0.5 × 0.3 × 0.3 mm grew
within 4 days. The crystals belong to the space group
P212121 with cell constants
a = 50.0 Å, b = 57.8 Å,
c = 74.3 Å and contain 1 elastase molecule per asymmetic unit. Crystals of the complex were soaked in a freezing solution consisting of 25% glycerol and 75% well solution (v/v) for
approximately 5 s and then flash frozen by immersing in liquid nitrogen.
X-ray data for the EI116-elastase crystal complex were collected at 100 K using a MAR300 image plate mounted on an Enraf Nonius rotating anode
generator operating at 40 kV and 80 mA to a resolution of 1.8 Å. Data
collection statistics are given in Table
I. X-ray data for the JD261-elastase
complex were collected on station 7.2 at the Daresbury synchrotron
source using a MAR 300 image plate to a resolution of 1.6 Å (Table
I).
-lactams form
different covalent complexes upon reaction with porcine elastase. The
high resolution x-ray structures of these two complexes provide a clear
insight into the mechanism of the reaction and suggest the design of a new class of serine protease inhibitors that resist enzyme reactivation by hydrolysis of the acyl intermediate. The presence of a hydroxyethyl substituent on the
-lactam ring provides a new reaction pathway resulting in the elimination of the hydroxyethyl group and the formation of a stabilizing conjugated double bond system. In contrast, the presence of a diethyl substituent on the
-lactam ring leads to
addition of water. The two enzyme complexes show very different binding
modes in the enzyme active site.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Lactam-related compounds are well established irreversible
inhibitors of a wide range of serine proteases including elastase (1),
-lactamase (2), phospholipase A2 (3), and bacterial signal
peptidases (4). Moreover, their efficacy as orally active inhibitors
has led to their widespread use in the clinic. In all cases a first
step in the inhibition process is acylation of the active site serine
by the
-lactam ring to generate a covalently bound acyl-enzyme
intermediate. Thereafter, the inhibitor may undergo a further
fragmentation resulting in a more stable entity that is resistant to
deacylation and hence regeneration of enzyme activity. In this study,
we report the discovery of a novel mode of action of a class of
monocyclic
-lactams, which results in a particularly stable
acyl-enzyme intermediate. The proposed mechanism, which is based on the
x-ray structures of the elastase-ligand complexes presented below, may
be generally applicable to other related serine proteases.
-lactams
bound to porcine pancreatic elastase
(PPE)1 have been reported,
the first involving a cephalosporin sulfone (8) and more recently an
N-sulfonylaryl
-lactam (9). In the latter case, the
monocyclic
-lactam simply acylates the active site serine residue
without further fragmentation. The class of monocyclic
-lactams
reported herein contain an aryloxy substituent at the C-4 position
(Fig. 1) that departs subsequent to
acylation of the serine residue. We have compared two related members
of this class of
-lactam that differ primarily in the nature of the
C-3 substituent. This difference results in distinct modes of action
upon reaction with elastase.

View larger version (20K):
[in a new window]
Fig. 1.
a and b,
structures of EI116 and JD261 and the proposed mechanisms for their
interaction with elastase. The structures of the starting ligands
are given at the top of the figure. The middle
panel shows likely covalently bound intermediates in which the
-lactam ring is cleaved and the OAr group on C-4 has left. The
bottom panel shows the formulae of the stable complexes as
determined in the two x-ray structures.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Data collection and refinement statistics
The structures were solved with the molecular replacement program AMoRe
(10) using the model of porcine pancreatic elastase from a published
crystal structure (entry 8EST in the Brookhaven Protein Data Base). All
water and ligand molecules were removed from the model structure.
Initial difference Fourier maps using phases calculated from the
molecular replacement solutions showed clear electron density for both
ligands. Subsequent refinement of all atom positions and individual
isotropic thermal parameters was carried out using SHELX-97 (11) (Table
I). A total of 282 water molecules were added to JD261 and 275 to EI116
using the program SHELXWAT (11). Both structures contained a calcium
and a sulfate ion as described in other published structures. Despite the short (5 s) soaking time in the cryoprotectant solution, a well
ordered glycerol molecule was located in the JD261-elastase complex.
Rounds of conjugate gradient least squares refinement were alternated
with examination of sigma weighted (2F(obs)
F(calc)) Fourier maps. This, along with the excellent
quality high resolution data, ensured that any model bias was
minimized. Once the R-factor had refined to a value of less
than 0.18 using all data, hydrogen atoms were added in calculated
positions. This reduced both the R-factor and the free
R-factor for both structures by more than 1% leading to
final R-factors of 0.16 with excellent geometries (Table I).
Coordinates of both structures have been deposited in the Brookhaven
Protein Data bank.
| |
RESULTS |
|---|
|
|
|---|
Geometry of JD261 and Interactions with the PPE Active
Site--
The ligand was clearly visible in an initial electron
density difference map. The excellent quality of the electron density calculated with data to a resolution of 1.60 Å shows that the ligand
derived from JD261 is planar between the ester carbon attached to the
serine and the nitrogen preceding the naphthalene ring system (Fig.
2). Furthermore, there is no trace of
substituents on positions 3 and 4 of the
-lactam. These observations
are consistent with the structures and mechanism shown in Fig.
1a.
|
The amide nitrogen atoms from
Gly-201(193)2 and
Ser-203(195) act as hydrogen bond donors to the ester carbonyl oxygen
atom, which lies in the oxyanion pocket. (Table
II and Fig.
3). The planar all trans
configuration of JD261 places constraints upon the orientation of the
urea moiety and only one other direct hydrogen bond can be formed
between the urea oxygen atom and Gln-200(192) (Fig. 3). The urea
nitrogen (N-1) is hydrogen bonded to a water molecule that forms a
bridging hydrogen bond to the amide nitrogen of Val-224(216). The
active site His-60(57) does not make any direct hydrogen bonds with
JD261 but does form a hydrogen bond to W751 (N
-2 ... W = 2.7Å). This water molecule is only 3.3 Å from the carbon of the ester
carbonyl and is well positioned to carry out a nucleophilic attack
along the Burgi-Dunitz trajectory (Fig. 3).
|
|
Geometry of EI116 and Interactions with the PPE Active Site-- The EI116 ligand product was clearly visible in an initial electron density difference map and showed the presence of both ethyl groups on C-3. The refined structure also showed clearly that position 4 is tetrahedral with a 1 atom substituent, consistent with the mechanism shown in Fig. 1b.
There are three hydrogen bonds linking the ligand directly to the
protein (Table II and Fig. 4). The
-lactam carbonyl group of the EI116 complex occupies almost the same
position in the oxyanion pocket as in JD261 and makes the same hydrogen
bonds. The N
-2 atom from His-60(57) acts as a hydrogen bond donor to the hydroxyl oxygen atom bonded to C(4). Additionally this hydroxyl group forms an intramolecular hydrogen bond to O
of the active site
serine. Binding of the ligand is also stabilized by van der Waals
interactions with Ser-222(214) and Phe-223(215) in binding pocket S2,
with Val-224(216) and Gln-200(192) in binding pocket S3 and by a
stacking interaction of the aromatic ring with the guanidinium group of
Arg-226(217A) in binding pocket S4.
|
| |
DISCUSSION |
|---|
|
|
|---|
Mechanism of
-Lactam Inhibition--
The x-ray structures of
the complexes are consistent with the mechanisms outlined in Fig. 1.
The mechanism shown for the reaction of EI116 with elastase is similar
to that proposed for a related series of compounds binding human
leukocyte elastase (12). In that work, mass spectrometry and NMR were
used to show acylation of the Ser-203(195), loss of the substituent on
C-4 of the lactam ring, and subsequent formation of the carbinolamine.
We can now show that the addition of water to the intermediate imine
results in a carbon with (S) configuration as predicted by modeling
studies (12). This hydroxyl group forms a hydrogen bond to His-60(57) and may play a role in the reactivation mechanism. Indeed this hydroxyl
group may be derived from the hydrolytic water molecule that is
required for deacylation and hence reactivation of elastase.
The new mechanism revealed by the binding of JD261 to elastase involves initial acylation of Ser-203(195) followed by loss of the OAr group from C-4. Thereafter, the hydroxyethyl substituent on C-3 provides an alternative pathway for reaction by a retro-aldol reaction to generate the acyl-enzyme intermediate with the concomitant release of acetaldehyde. This results in the planar conjugated intermediate shown in Fig. 1 and as a consequence there is no possibility of addition of water to C-4. The identity of the acylated enzyme complexes have both been verified using electrospray ionization mass spectrometry, and the masses of these covalent intermediates correspond to the major molecular species.
Comparison of Binding Modes of EI116 and JD261 with Peptide
Analogue Compounds--
Atomic coordinates are available for 26 PPE
x-ray structures. Protein inhibitor·PPE complexes include those with
elafin (13), chymotrypsin elastase inhibitor(14), and a heptamer from
-casomorphin-7 (15). Small molecule inhibitor complexes include:
peptidyl fluoromethyl ketones (16-19), peptidyl chloromethyl
ketones (20), peptidyl boronic acids (21), isocoumarin derivatives
(22-24), peptidylketobenzoxazoles (25), and a peptidomimetic aminimide
(26). In all cases the elastase active site maintains the same shape,
and typical root mean square differences between backbone atoms are
less than 0.3 Å. The side chains Gln-200(192) and Arg-226(217A) can
adopt different conformations and these changes are particularly
pronounced in the complex with JD261 where a very different
conformation of the Gln-200(192) is required to make way for the
naphthyl group of the ligand (Figs. 3 and 4). The unique placement of
this ligand compared with all other published classes of inhibitor
gives an indication of the relative lack of flexibility caused by its
all-trans configuration and charge delocalized structure.
The x-ray structure of
trifluoroacetyl-Lys-Phe-p-isopropylanilide/PPE defined a new subsite for the anilide group, which was located under the side chain
of Gln-200(192) (19). One ring of the naphthyl group of JD261 partly
overlaps this site; however, the uniquely different conformation of
Gln-200(192) in this structure provides a rather differently shaped pocket.
The position of EI116 in the active site resembles the binding
adopted by other peptide-type inhibitors (16) in which the peptide side chains fill the specificity pockets S1 to S4. The closest
similarity occurs with the trifluoroacetyl dipeptidyl isopropylanilide
family of inhibitors (18). The S1 pocket is filled in this family by
the trifluoroacetyl group, whereas EI116 fills the S1 pocket quite
efficiently with one of the ethyl groups on what was C-3 of the
-lactam. The S4 subsite accommodates the aromatic anilide group,
which lies in the same place as the bromphenyl group of EI116. The
presence of the aromatic group causes a significant shift in the
position of the side chain of Arg-226(217A), which forms van der Waals
contacts with the group.
The main-chain structures of elastase bound to EI116 and JD261 show an
unexpected conformational difference from residues Asn-99(95)-Thr-100(96)-Asp-101(97)-Asp-102(98). All 26 available published x-ray structures of PPE complexes show these residues in a
type I
-turn. The electron density in the EI116 complex clearly
shows a
II turn despite the fact that there are no direct interactions with the ligand that may have induced the change.
Implications of Structure for Reactivation--
It has been shown
that reactivation of human leukocyte elastase-inhibitor complexes, of a
series of substituted mono-
-lactams, results in a half-life of
between 3 and 15 h. Stability of the complex is insensitive to
increasing ionic strength and also to the nature of the leaving group
on C-4 but does however depend on the nature of the substituted urea
(1).
An unmodified heptapeptide complexed with elastase (15) has been found
to form an acyl-complex with Ser-203(195) through the C-terminal
carboxy group. The x-ray crystal structure of this complex shows the
presence of a water molecule hydrogen bonded to N
-2 of His-60(57)
and in an ideal position to attack the carbon of the ester carbonyl. A
mechanism has been proposed that explains the cleavage of the
acyl-enzyme intermediate by a hydroxide ion that is derived by
deprotonation of a water molecule by His-60(57) (15). The structure of
the JD216 complex has an identically positioned water molecule.
However, the presence of the conjugated double bond is likely to confer
hydrolytic stability on the acyl-enzyme intermediate as has been
previously noted by the inhibition of
-lactamase by clavulanic acid
(27-29). JD261 is therefore an example of a new class of serine
protease inhibitor that provides a novel chemical mechanism for
resisting reactivation. We are currently exploring the generality of
this mechanism with proteases other than elastase.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed. E-mail: m.walkinshaw@ed.ac.uk.
2 The numbering nomenclature for PPE is taken from Mattos et al. (18) in which amino acid residues of PPE are numbered sequentially beginning with Val-16(16) and ending with Asn-255(245). In this scheme, residues of the catalytic triad are Ser-203(195), His-60(57), Asp-108(102).
| |
ABBREVIATIONS |
|---|
The abbreviation used is: PPE, porcine pancreatic elastase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Green, B. G., Chabin, R., Mills, S., Underwood, D. J., Shah, S. K., Kuo, D., Gale, P., Maycock, A. L., Liesch, J., Burgey, C. S., Doherty, J. B., Dorn, C. P., Finke, P. E., Hagmann, W. K., Hale, J. J., Maccoss, M., Westler, W. M., and Knight, W. B. (1995) Biochemistry 34, 14331-14343[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Strynadka, N. C. J., Adachi, H., Jensen, S. E., Johns, K., Sielecki, A., Betzel, C., Sutoh, K., and James, M. N. G. (1992) Nature 359, 700-705[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Tew, D. G., Boyd, H. F., Ashman, S., Theobald, C., and Leach, C. A. (1998) Biochemistry 37, 10087-10093[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Paetzel, M., Dalbey, R. E., and Strynadka, N. C. J. (1998) Nature 396, 186-190[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Kerrigan, J. E., Oleksyszyn, J., Kam, C. M., Selzler, J., and Powers, J. C. (1995) J. Med. Chem. 38, 544-552[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Birrer, P., Mcelvaney, N. G., Rudeberg, A., Sommer, C. W., Liechtigallati, S., Kraemer, R., Hubbard, R., and Crystal, R. G. (1994) Am. J. Respir. Crit. Care Med. 150, 207-213[Abstract] |
| 7. | Janusz, M. J., and Durham, S. L. (1997) Inflamm. Res. 46, 503-508[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Navia, M. A., Springer, J. P., Lin, T. Y., Williams, H. R., Firestone, R. A., Pisano, J. M., Doherty, J. B., Finke, P. E., and Hoogsteen, K. (1987) Nature 327, 79-82[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Wilmouth, R. C., Westwood, N. J., Anderson, K., Brownlee, W., Claridge, T. D. W., Clifton, I. J., Pritchard, G. J., Aplin, R. T., and Schofield, C. J. (1998) Biochemistry 37, 17506-17513[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Navaza, J. (1994) Acta Crystallogr. Sect. A 50, 157-163[CrossRef] |
| 11. | Sheldrick, G. M. (1997) SHELX-97 University of Goettingen, Germany |
| 12. | Underwood, D. J., Green, B. G., Chabin, R., Mills, S., Doherty, J. B., Finke, P. E., Maccoss, M., Shah, S. K., Burgey, C. S., Dickinson, T. A., Griffin, P. R., Lee, T. E., Swiderek, K. M., Covey, T., Westler, W. M., and Knight, W. B. (1995) Biochemistry 34, 14344-14355[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Tsunemi, M., Matsuura, Y., Sakakibara, S., and Katsube, Y. (1996) Biochemistry 35, 11570-11576[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Huang, K., Strynadka, N. C. J., Bernard, V. D., Peanasky, R. J., and James, M. N. G. (1994) Structure 2, 679-689[Medline] [Order article via Infotrieve] |
| 15. | Wilmouth, R. C., Clifton, I. J., Robinson, C. V., Roach, P. L., Aplin, R. T., Westwood, N. J., Hajdu, J., and Schofield, C. J. (1997) Nat. Struct. Biol. 4, 456-462[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Bode, W., Meyer, E., and Powers, J. C. (1989) Biochemistry 28, 1951-1963[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Takahashi, L. H., Radhakrishnan, R., Rosenfield, R. E., Meyer, E. F., Trainor, D. A., and Stein, M. (1988) J. Mol. Biol. 201, 423-428[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Mattos, C., Giammona, D. A., Petsko, G. A., and Ringe, D. (1995) Biochemistry 34, 3193-3203[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Mattos, C., Rasmussen, B., Ding, X. C., Petsko, G. A., and Ringe, D. (1994) Nat. Struct. Biol. 1, 55-58[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Wei, A. Z., Mayr, I., and Bode, W. (1988) FEBS Lett. 234, 367-373[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Takahashi, L. H., Radhakrishnan, R., Rosenfield, R. E., and Meyer, E. F. (1989) Biochemistry 28, 7610-7617[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Powers, J. C., Oleksyszyn, J., Narasimhan, S. L., Kam, C. M., Radhakrishnan, R., and Meyer, E. F. (1990) Biochemistry 29, 3108-3118[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Vijayalakshmi, J., Meyer, E. F., Kam, C. M., and Powers, J. C. (1991) Biochemistry 30, 2175-2183[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Hernandez, M. A., Powers, J. C., Glinski, J., Oleksyszyn, J., Vijayalakshmi, J., and Meyer, E. F. (1992) J. Med. Chem. 35, 1121-1129[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Edwards, P. D., Meyer, E. F., Vijayalakshmi, J., Tuthill, P. A., Andisik, D. A., Gomes, B., and Strimpler, A. (1992) J. Am. Chem. Soc. 114, 1854-1863[CrossRef] |
| 26. |
Peisach, E.,
Casebier, D.,
Gallion, S. L.,
Furth, P.,
Petsko, G. A.,
Hogan, J. C.,
and Ringe, D.
(1995)
Science
269,
66-69 |
| 27. | Knowles, J. R. (1985) Acc. Chem. Res. 18, 97-104 |
| 28. | Chen, C. C. H., and Herzberg, O. (1992) J. Mol. Biol. 224, 1103-1113[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Brown, R. P. A., Aplin, R. T., and Schofield, C. J. (1996) Biochemistry 35, 12421-12432[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950 [CrossRef] |
This article has been cited by other articles:
![]() |
I. Dell'Aica, L. Sartor, P. Galletti, D. Giacomini, A. Quintavalla, F. Calabrese, C. Giacometti, E. Brunetta, F. Piazza, C. Agostini, et al. Inhibition of Leukocyte Elastase, Polymorphonuclear Chemoinvasion, and Inflammation-Triggered Pulmonary Fibrosis by a 4-Alkyliden-beta-lactam with a Galloyl Moiety J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 539 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kulanthaivel, A. J. Kreuzman, M. A. Strege, M. D. Belvo, T. A. Smitka, M. Clemens, J. R. Swartling, K. L. Minton, F. Zheng, E. L. Angleton, et al. Novel Lipoglycopeptides as Inhibitors of Bacterial Signal Peptidase I J. Biol. Chem., August 27, 2004; 279(35): 36250 - 36258. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |